Amylyx Pharmaceuticals, Inc.
AMLX
Rang in Aktien
#4617
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aktienkurs
$26.28
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.30B
Veränderung (1 Tag)
-4.95%
Veränderung (1 Jahr)
75.79%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategorie
Healthcare
EPS für Amylyx Pharmaceuticals, Inc. (AMLX)
EPS zum June 2026 TTM: $-1.41
Laut den aktuellen Finanzberichten und dem Aktienkurs von Amylyx Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-1.41. Am Ende des Jahres 2023 betrug das EPS $0.73 eine Steigerung gegenüber dem EPS von 2022, das $-2.98 betrug.
EPS-Verlauf von Amylyx Pharmaceuticals, Inc. von 2019 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
